SCHEMBL10030736

SCHEMBL10030736

CCCOc1ccccc1OCC(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.46
CYP1A2 P05177 3/20 0.43
CYP2C19 P33261 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 2/20 0.43
HPGD P15428 1/20 0.43
MAPT P10636 4/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
USP2 O75604 2/20 0.41
ALDH1A1 P00352 2/20 0.41
CASP1 P29466 2/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
THRB P10828 1/20 0.41
G6PD P11413 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28288419 0.85 MAPT (0.52) L3MBTL1HPGDMAPTNPSR1KDM4E
SCHEMBL10316560 0.84 L3MBTL1 (0.53) L3MBTL1CYP1A2CYP2C19TDP1CYP2D6
1,2-Dipropoxybenzene SCHEMBL578657 0.83 CYP1A2 (0.56) L3MBTL1CYP1A2CYP2C19TDP1CYP2D6
1,2-Dipropoxybenzene SCHEMBL29428926 0.83 CYP1A2 (0.56) L3MBTL1CYP1A2CYP2C19TDP1CYP2D6
1,2-Dipropoxybenzene SCHEMBL8910053 0.81 CYP1A2 (0.54) L3MBTL1CYP1A2CYP2C19TDP1CYP2D6
SCHEMBL2380358 0.81 L3MBTL1 (0.41) L3MBTL1CYP1A2CYP2C19TDP1CYP2D6
SCHEMBL2350644 0.81 AR (0.47) L3MBTL1MAPTNPSR1KDM4EMEN1
SCHEMBL15473260 0.81 RXRA (0.46) L3MBTL1CYP1A2CYP2C19TDP1CYP2D6
SCHEMBL21385775 0.81 L3MBTL1 (0.41) L3MBTL1CYP1A2CYP2C19TDP1CYP2D6
SCHEMBL31186659 0.81 L3MBTL1 (0.41) L3MBTL1CYP1A2CYP2C19TDP1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938239-B2 Method for preparing silodosin SANDOZ AG (CH) 2018-04-10 US disclosed
US-9932308-B2 Method for producing indoline compound UBE INDUSTRIES, LTD. (JP) 2018-04-03 US disclosed
US-9745264-B2 Method for preparing silodosin and intermediate thereof SHANGHAI SYNCORES TECHNOLOGIES, INC. (CN) 2017-08-29 US disclosed
US-20170197917-A1 METHOD FOR PRODUCING INDOLINE COMPOUND UBE INDUSTRIES, LTD. (JP) 2017-07-13 US disclosed
US-9643921-B2 Method for producing indoline compound UBE INDUSTRIES, LTD. (JP) 2017-05-09 US disclosed
US-20170008842-A1 METHOD FOR PRODUCING INDOLINE COMPOUND UBE INDUSTRIES, LTD. (JP) 2017-01-12 US disclosed
EP-3103794-A1 METHOD FOR PRODUCING INDOLINE COMPOUND UBE Industries, Ltd. (JP) 2016-12-14 EP disclosed
US-20160304452-A1 METHOD FOR PREPARING SILODOSIN AND INTERMEDIATE THEREOF ZHEJIANG HUAHAI PHARMACEUTICALS CO., LTD. (CN) 2016-10-20 US disclosed
US-20160176818-A1 Method For Preparing Silodosin SANDOZ AG (CH) 2016-06-23 US disclosed
US-20150038727-A1 METHOD FOR PREPARING SILODOSIN SANDOZ AG (CH) 2015-02-05 US disclosed
US-8471039-B2 Process for the preparation of indoline derivatives and their intermediates thereof SANDOZ AG (CH) 2013-06-25 US disclosed
US-20120165548-A1 PROCESS FOR THE PREPARATION OF INDOLINE DERIVATIVES AND THEIR INTERMEDIATES THEREOF SANDOZ AG (IN) 2012-06-28 US disclosed
US-7834193-B2 Indoline compound and process for producing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 US disclosed
US-20070197627-A1 Indoline compound and process for producting the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165548-A1 PROCESS FOR THE PREPARATION OF INDOLINE DERIVATIVES AND THEIR INTERMEDIATES THEREOF PIR, CYP3A4, CYP4A11 L3MBTL1 4821/4885CYP1A2 13/4885CYP2C19 73/4885
US-20160176818-A1 Method For Preparing Silodosin RCC2, RIOX2, CYP51A1 L3MBTL1 3283/4885CYP1A2 368/4885CYP2C19 1115/4885
US-20150038727-A1 METHOD FOR PREPARING SILODOSIN RCC2, RIOX2, CYP51A1 L3MBTL1 3283/4885CYP1A2 368/4885CYP2C19 1115/4885
US-20170008842-A1 METHOD FOR PRODUCING INDOLINE COMPOUND INMT, TPH1, IDO1 L3MBTL1 4410/4885CYP1A2 107/4885CYP2C19 135/4885
US-20160304452-A1 METHOD FOR PREPARING SILODOSIN AND INTERMEDIATE THEREOF PTMA, PIR, ERG28 L3MBTL1 3673/4885CYP1A2 436/4885CYP2C19 1588/4885
US-20070197627-A1 Indoline compound and process for producting the same BPHL, DAO, INHA L3MBTL1 3972/4885CYP1A2 1443/4885CYP2C19 2629/4885
US-20170197917-A1 METHOD FOR PRODUCING INDOLINE COMPOUND INMT, TPH1, INPP5A L3MBTL1 4755/4885CYP1A2 355/4885CYP2C19 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.